Lenvatinib and Pembrolizumab Simultaneous Combination Study
- Status
- COMPLETED
- Phase
- PHASE2
Clinical Trials Related to Lenvatinib
Related studies linked through entity extraction aliases.
A Study to Evaluate the Safety and Efficacy of Lenvatinib in Participants With Refractory Differentiated Thyroid Cancer
- Status
- COMPLETED
- Phase
- PHASE4
Study of MK-4830 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-4830-001)
- Status
- COMPLETED
- Phase
- PHASE1
Expanded Access Program With Lenvatinib for the Treatment of Differentiated Thyroid Cancer in Brazil
- Status
- APPROVED_FOR_MARKETING
- Phase
- N/A
Lenvatinib and Eribulin in Advanced Soft Tissue Sarcoma
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Lenvatinib in Combination With Pembrolizumab Versus Treatment of Physician's Choice in Participants With Advanced Endometrial Cancer (MK-3475-775/E7080-G000-309 Per Merck Standard Convention [KEYNOTE-775])
- Status
- COMPLETED
- Phase
- PHASE3
A Study of Biomarker-Directed, Pembrolizumab (MK-3475) Based Combination Therapy for Advanced Non-Small Cell Lung Cancer (MK-3475-495/KEYNOTE-495)
- Status
- COMPLETED
- Phase
- PHASE2
Lenvatinib and Iodine Therapy in Treating Patients With Radioactive Iodine-Sensitive Differentiated Thyroid Cancer
- Status
- TERMINATED
- Phase
- PHASE2
Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)
- Status
- RECRUITING
- Phase
- PHASE3
Trial to Evaluate Safety and Efficacy of Treatment of Physician Choice (TPC) Following First-Line Treatment of Lenvatinib in Subjects With Unresectable Hepatocellular Carcinoma (uHCC)
- Status
- TERMINATED
- Phase
- PHASE2
A Study of Lenvatinib Plus Nivolumab in Participants With Hepatocellular Carcinoma
- Status
- COMPLETED
- Phase
- PHASE1
Lenvatinib and Everolimus in Renal Cell Carcinoma (RCC)
- Status
- COMPLETED
- Phase
- PHASE1
A Phase II a Study of Lenvatinib, a Multi-targeted Tyrosine Kinase Inhibitor, Combined With Pembrolizumab (PD-1 Inhibitor) for the Treatment of Metastatic Gastroesophageal Cancer Patients Who Have Progressed on First or Subsequent Line Therapies
- Status
- COMPLETED
- Phase
- PHASE2
Neoadjuvant Treatment Associated With Maintenance Therapy by Anti-PD1 Immunotherapy in Patients With Resectable Head and Neck Mucosal Melanoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Phase II Study of Pembrolizumab and Lenvatinib in Advanced Well-differentiated Neuroendocrine Tumors
- Status
- COMPLETED
- Phase
- PHASE2
Study of Lenvatinib in Combination With Everolimus in Recurrent and Refractory Pediatric Solid Tumors, Including Central Nervous System Tumors
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Trial to Assess Safety and Efficacy of Lenvatinib (18 mg vs. 14 mg) in Combination With Everolimus in Participants With Renal Cell Carcinoma
- Status
- COMPLETED
- Phase
- PHASE2
Phase II Study of Single Agent Lenvatinib
- Status
- UNKNOWN
- Phase
- PHASE2
UPCC 36315 A Phase II Study Of Everolimus (RAD001) And Lenvatinib (E7080) In Patients With Metastatic Differentiated Thyroid Cancer Who Have Progressed on Lenvatinib Alone
- Status
- SUSPENDED
- Phase
- PHASE2
Pharmacokinetic Study of E7080/Lenvatinib in Chinese Subjects With Solid Tumor
- Status
- COMPLETED
- Phase
- PHASE1